Ascendis Pharma A/S
ASND
182 hedge funds and large institutions have $6.89B invested in Ascendis Pharma A/S in 2022 Q3 according to their latest regulatory filings, with 37 funds opening new positions, 65 increasing their positions, 50 reducing their positions, and 21 closing their positions.
996% more call options, than puts
Call options by funds: $225M | Put options by funds: $20.5M
76% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 21
30% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 50
17% more capital invested
Capital invested by funds: $5.88B → $6.89B (+$1.02B)
9% more funds holding
Funds holding: 167 → 182 (+15)
7% more funds holding in top 10
Funds holding in top 10: 15 → 16 (+1)
6.14% more ownership
Funds ownership: 110.98% → 117.12% (+6.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$75.8M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
+$54.5M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$36.4M |
| 4 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$33.1M |
| 5 |
LGM
Logos Global Management
San Francisco,
California
|
+$23.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$122M |
| 2 |
Goldman Sachs
New York
|
-$43.4M |
| 3 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$30.7M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$25.7M |
| 5 |
SCM
Spyglass Capital Management
San Francisco,
California
|
-$15.1M |
ASND Hedge Fund Activity: Q3 2022 in Review
182 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma A/S (ASND) for Q3 2022, worth a combined $6.89B — up 17% from $5.88B a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new ASND positions and 21 closed out — a net gain of 16 holders — while 65 added to existing stakes and 50 trimmed.
The largest buyer was Deep Track Capital, opening a new position worth an estimated $75.8M. The largest seller was T. Rowe Price Associates, cutting an estimated $122M.
- 182 institutional investors held Ascendis Pharma A/S (ASND) as of Q3 2022, up from 167 in Q2 2022.
- Funds reported $6.89B of Ascendis Pharma A/S stock for Q3 2022, up 17% quarter-over-quarter.
- 37 funds opened new Ascendis Pharma A/S positions in Q3 2022 and 21 closed out, a net change of +16 holders.
- The largest Ascendis Pharma A/S buyer in Q3 2022 was Deep Track Capital, an estimated $75.8M added.
- The largest Ascendis Pharma A/S seller in Q3 2022 was T. Rowe Price Associates, an estimated $122M sold.
Based on aggregated 13F filings for Q3 2022.